Capha Pharmaceuticals (FPSUF) Stock Statistics & Valuation Metrics

Capha Pharmaceuticals has a market cap or net worth of $64.00. The enterprise value is ―.

Capha Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Capha Pharmaceuticals’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 485.83%.

The current PE Ratio of Capha Pharmaceuticals is ―. Capha Pharmaceuticals’s PEG ratio is -0.00349.

In the last 12 months, Capha Pharmaceuticals had revenue of 0.00 and earned -70.77K in profits. Earnings per share was 0.00.

In the last 12 months, operating cash flow was -50.80K and capital expenditures 0.00, giving a free cash flow of -50.80K billion.

Capha Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Capha Pharmaceuticals upcoming earnings date is Apr 24, 2026, TBA (Confirmed).

Capha Pharmaceuticals as a current ratio of <0.01, with Debt / Equity ratio of -99.22%

In the past 12 months, Capha Pharmaceuticals has paid 0.00 in taxes.

Capha Pharmaceuticals EV to EBITDA ratio is -11.21, with an EV/FCF ratio of -8.01.

Capha Pharmaceuticals has $3.38K in cash and marketable securities with $589.57K in debt, giving a net cash position of -$586.19K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Capha Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―